Trichuris suis ova - Fortress Biotech
Alternative Names: CNDO-201; TSO; TSO 2500; TSO 7500Latest Information Update: 02 Oct 2021
At a glance
- Originator University of Iowa Research Foundation
- Developer Charite of Berlin; Dr Falk Pharma; Fortress Biotech; Hadassah Medical Organization; Icahn School of Medicine at Mount Sinai; National Institutes of Health (USA); University of Wisconsin-Madison
- Class Eukaryota; Immunotherapies; Probiotics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Autistic disorder; Crohn's disease; Multiple sclerosis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Type 1 diabetes mellitus; Ulcerative colitis
Most Recent Events
- 29 Jul 2016 Immanuel Krankenhaus Berlin terminates phase II TSORA trial in Rheumatoid arthritis (adjunctive therapy) in Germany (EudraCT2011-006344-71)
- 05 May 2016 Charite University terminates phase II trial in Multiple sclerosis in Germany (EudraCT2009-015319-41)
- 01 Feb 2016 Hadassah Medical Organization terminates a phase II trial in Autistic disorder in Israel due to lack of significant efficacy (NCT01734941)